Simultaneous blockade of the CD73 / EGFR axis inhibits tumor growth
IUBMB Life · 2025
DOI: 10.1002/iub.2933 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Keivan Ardeshiri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: ErbB Receptors, 5'-Nucleotidase, Cell Proliferation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Tabriz University of Medical Sciences.
Abstract (Originalsprache)
Targeting the influencing factors in tumor growth and expansion in the tumor microenvironment is one of the key approaches to cancer immunotherapy. Various factors in the tumor microenvironment can in cooperation stimulate tumor growth, suppress anti‐tumor immune responses, promote drug resistance, and ultimately enhance tumor recurrence. Therefore, due to the dependence and close cooperation of these axes, their combined targeting can have a greater effect compared to their individual targeting. Among the important factors affecting tumor growth in the tumor region, CD73 and EGFR play an important role in tumor growth by stimulating each other's expression and function. Therefore, we intended to use the nanocarriers that we had previously produced and characterized to deliver anti‐CD73 and EGFR siRNAs to murine breast cancer 4T1 cells. Silencing CD73 and EGFR could significantly induce cell death in cancer cells. Downregulation of the CD73/EGFR axis also suppressed the migratory and proliferative potential of cancer cells. This therapeutic strategy also inhibited tumor growth in in ovo model. These findings imply that simultaneous targeting of CD73 and EGFR in breast cancer can be considered a novel immunotherapeutic approach that needs further investigation in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
- Immunogenetics Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Paramedicine, Amol School of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran.
- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
ORCID-Profile: Farhad Jadidi
Förderung
- Tabriz University of Medical Sciences
Zitieren
APA
Ardeshiri, K., Hassannia, H., Ghalamfarsa, G., Jafary, H., & Jadidi, F. (2025). Simultaneous blockade of the CD73 / EGFR axis inhibits tumor growth. IUBMB Life. https://doi.org/10.1002/iub.2933
Vancouver
Ardeshiri K, Hassannia H, Ghalamfarsa G, Jafary H, Jadidi F. Simultaneous blockade of the CD73 / EGFR axis inhibits tumor growth. IUBMB Life. 2025. doi:10.1002/iub.2933
BibTeX
@article{Ardeshiri2025,
author = {Ardeshiri, Keivan and Hassannia, Hadi and Ghalamfarsa, Ghasem and Jafary, Hanieh and Jadidi, Farhad},
title = {Simultaneous blockade of the CD73 / EGFR axis inhibits tumor growth},
journal = {IUBMB Life},
year = {2025},
doi = {10.1002/iub.2933}
}
EUVIMED